Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Quince Therapeutics, Inc. (QNCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: QNCX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $7.25
Year Target Price $7.25
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 149.51% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 80.82M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) - | Beta 0.8 | 52 Weeks Range 0.51 - 2.45 | Updated Date 06/29/2025 |
52 Weeks Range 0.51 - 2.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.8% | Return on Equity (TTM) -130.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64709396 | Price to Sales(TTM) - |
Enterprise Value 64709396 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.44 | Shares Outstanding 52140700 | Shares Floating 36523709 |
Shares Outstanding 52140700 | Shares Floating 36523709 | ||
Percent Insiders 13.14 | Percent Institutions 22.25 |
Analyst Ratings
Rating 4.75 | Target Price 7.25 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quince Therapeutics, Inc.
Company Overview
History and Background
Quince Therapeutics, Inc., previously known as Cortexyme, was founded in 2013. Initially focused on Alzheimer's disease, the company underwent a strategic shift, including rebranding to Quince Therapeutics, to focus on bone-targeting therapeutics. Key milestones include clinical trial initiations and acquisitions to expand their pipeline.
Core Business Areas
- Bone-Targeting Therapeutics: Focuses on developing innovative therapies for bone diseases, including fracture non-union and osteogenesis imperfecta. Lead candidates include setrusumab and remibrutinib.
Leadership and Structure
The leadership team includes Dirk Thye, CEO. The organizational structure is typical of a biotech company, with departments for research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Setrusumab: An anti-sclerostin monoclonal antibody being developed for osteogenesis imperfecta (OI). It's in clinical development, and no market share data is available yet as it's not approved. Competitors in OI treatments include bisphosphonates. Market for OI treatment is fragmented. If approved, setrusumab will compete with biologics from companies like Ascendis Pharma (ASND). Revenue projections not available pending approval.
- Remibrutinib: An oral, selective BTK inhibitor initially licensed to Kinnate Biopharma and then reclaimed by Quince. Kinnate developed the medication but halted clinical trials and returned rights to Quince. Quince is actively pursuing strategic alternatives for the product.
Market Dynamics
Industry Overview
The biotech industry is characterized by high risk, high reward, and significant regulatory hurdles. Bone disease therapeutics represents a significant area with unmet needs and increasing aging populations.
Positioning
Quince Therapeutics is positioned as a company specializing in bone-targeting therapeutics. Their competitive advantage lies in their specific focus and novel therapeutic approach.
Total Addressable Market (TAM)
The TAM for osteogenesis imperfecta and fracture non-union is estimated to be billions of dollars globally. Quince Therapeutics is positioned to capture a significant portion of this market if their lead candidate, setrusumab, is approved.
Upturn SWOT Analysis
Strengths
- Targeted therapeutic approach
- Experienced management team
- Strong intellectual property portfolio
- Novel pipeline assets
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High cash burn rate
- Remibrutinib development uncertain
Opportunities
- Partnerships and collaborations
- Expansion into new indications
- Potential for breakthrough therapies
- Acquisition or licensing of additional assets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
- Funding risk
Competitors and Market Share
Key Competitors
- ASND
- BMY
- LLY
Competitive Landscape
Quince faces competition from established pharmaceutical companies in the bone disease and immunology spaces. Their advantage lies in their targeted approach and focus on specific patient populations.
Growth Trajectory and Initiatives
Historical Growth: Quince's historical growth has been centered around advancing their clinical pipeline.
Future Projections: Future growth depends on clinical trial outcomes for setrusumab and the potential development of remibrutinib or other assets. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing on setrusumab development, securing financing, and evaluating strategic options for remibrutinib.
Summary
Quince Therapeutics is a clinical-stage biopharmaceutical company focused on bone-targeting therapeutics. The company's success hinges on the clinical development of setrusumab for osteogenesis imperfecta. Their cash position needs to be watched carefully. Quince needs to execute its clinical trials well to maintain investor confidence and needs to seek out a partner for drug development or commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Quince Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on the most recent publicly available information. Market share data is estimated and may not be precise. Investing in biotech companies is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quince Therapeutics, Inc.
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-09 | CEO, Chief Medical Officer & Director Dr. Dirk Thye M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.quincetx.com |
Full time employees 36 | Website https://www.quincetx.com | ||
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.